Artiva Biotherapeutics Shows Promising AlloNK Data Across Autoimmune Diseases

  • Artiva Biotherapeutics will present updated AlloNK® data at ACR Convergence 2026, including results from 34 patients across rheumatoid arthritis, Sjögren disease, and systemic sclerosis.
  • Oral presentation highlights robust efficacy responses comparable to CAR T-cell therapies in refractory rheumatoid arthritis patients.
  • Poster presentations detail favorable safety profile and deep B-cell depletion in 60 patients with rheumatological diseases.
  • Phase 3 registrational trial for refractory rheumatoid arthritis is set to begin in the second half of 2026.

Artiva Biotherapeutics is positioning AlloNK as a scalable, outpatient-administered treatment for refractory autoimmune diseases, aiming to fill a critical gap in the market. The upcoming Phase 3 trial and promising early data could set the stage for a new standard in B-cell depletion therapies. The company's focus on accessibility and safety may attract both investors and patients in a competitive biotech landscape.

Clinical Efficacy
Whether AlloNK's efficacy data in refractory rheumatoid arthritis can position it as a competitive alternative to CAR T-cell therapies.
Regulatory Pathway
The pace at which Artiva can advance its Phase 3 trial and secure regulatory approval for AlloNK.
Market Differentiation
How Artiva's outpatient-administered, non-genetically modified NK cell therapy will compete in the autoimmune disease treatment landscape.